Adding CBG to CBD Cut the Anti-Seizure Dose Needed by Half

Animal study in mice using the maximal electroshock seizure (MES) model. CBD and CBG administered intraperitoneally, alone and in 1:1 combination. Full dose-response and dose-toxicity curves generated for each compound and the combination. ED50 and TD50 calculated to determine therapeutic indices.

Finding a non-psychoactive potentiator for CBD's anti-seizure effects could be clinically transformative. If CBG allows CBD doses to be halved while maintaining seizure protection, patients could potentially achieve the same benefit with fewer side effects (since many CBD side effects are dose-dependent). This is especially relevant for pediatric epilepsy patients where minimizing drug burden is a priority.

This is the final piece in the epilepsy cluster in this database, connecting to CBD's clinical epilepsy evidence (RTHC-00160, RTHC-00165, RTHC-00186, RTHC-00189, RTHC-00190) and the computational modeling of CBD's seizure mechanisms (RTHC-00238). The hemp neuroprotection review (RTHC-00271) noted that non-cannabinoid compounds may contribute to therapeutic effects — CBG represents another cannabinoid class that could expand the epilepsy treatment toolkit beyond CBD alone. The 'entourage effect' concept gets concrete evidence here: CBD works better for seizures when combined with another cannabinoid.

Animal model — the MES model is a standard seizure screening tool but doesn't capture all epilepsy types. Only a 1:1 CBD:CBG ratio was tested; other ratios may produce different potency and toxicity profiles. Intraperitoneal injection doesn't model oral drug delivery. The 40% reduction in TD50 (increased toxicity) partially offsets the potency gain and needs careful evaluation. Mouse pharmacokinetics differ from human.